TY - JOUR
T1 - Chlamydia pneumoniae infection of lungs and macrophages indirectly stimulates the phenotypic conversion of smooth muscle cells and mesenchymal stem cells
T2 - Potential roles in vascular calcification and fibrosis
AU - Cabbage, Sarah
AU - Ieronimakis, Nicholas
AU - Preusch, Michael
AU - Lee, Amy
AU - Ricks, Jerry
AU - Janebodin, Kajohnkiart
AU - Hays, Aislinn
AU - Wijelath, Errol S.
AU - Reyes, Morayma
AU - Campbell, Lee Ann
AU - Rosenfeld, Michael E.
N1 - Publisher Copyright:
© 2014 Federation of European Microbiological Societies.
PY - 2014/10/1
Y1 - 2014/10/1
N2 - Two hallmarks of advanced atherosclerosis are calcification and fibrosis. We hypothesized that Chlamydia pneumoniae infection may contribute to atherosclerosis by inducing the conversion of vascular smooth muscle cells to calcifying cells or by converting mesenchymal stem cells to osteochondrocytic or fibroblastic phenotypes. In this study, direct infection of bovine aortic smooth muscle cells (BSMCs) did not induce the expression of alkaline phosphatase or the deposition of extracellular calcium phosphate. However, conditioned media from C. pneumoniae-infected macrophages accelerated conversion of BSMCs to a calcifying phenotype. Treatment of the conditioned media with an anti-TNF-alpha blocking antibody abrogated this stimulatory effect. Treatment of perivascular Sca-1+, CD31-, CD45- cells from apoE-/- mouse aortas with the conditioned media from infected macrophages induced the Sca-1+ cells to produce collagen II, an additional marker of an osteochondrocytic phenotype. Treatment of mouse coronary perivascular Sca-1+, CD31-, CD45- cells with the supernatant from homogenates of C. pneumoniae-infected mouse lungs as compared to noninfected lungs induced expression of the Collagen 1α1 gene and deposition of collagen. Therefore, an increase in plasma cytokines or other factors in response to respiratory infection with C. pneumoniae or infection of macrophages within the blood vessel could contribute to both calcification and fibrosis of advanced atherosclerotic lesions. Pseudomonas aeruginosa is equipped with a large arsenal of cell-associated and secreted virulence factors and can use them together to enhance its own virulence potential.
AB - Two hallmarks of advanced atherosclerosis are calcification and fibrosis. We hypothesized that Chlamydia pneumoniae infection may contribute to atherosclerosis by inducing the conversion of vascular smooth muscle cells to calcifying cells or by converting mesenchymal stem cells to osteochondrocytic or fibroblastic phenotypes. In this study, direct infection of bovine aortic smooth muscle cells (BSMCs) did not induce the expression of alkaline phosphatase or the deposition of extracellular calcium phosphate. However, conditioned media from C. pneumoniae-infected macrophages accelerated conversion of BSMCs to a calcifying phenotype. Treatment of the conditioned media with an anti-TNF-alpha blocking antibody abrogated this stimulatory effect. Treatment of perivascular Sca-1+, CD31-, CD45- cells from apoE-/- mouse aortas with the conditioned media from infected macrophages induced the Sca-1+ cells to produce collagen II, an additional marker of an osteochondrocytic phenotype. Treatment of mouse coronary perivascular Sca-1+, CD31-, CD45- cells with the supernatant from homogenates of C. pneumoniae-infected mouse lungs as compared to noninfected lungs induced expression of the Collagen 1α1 gene and deposition of collagen. Therefore, an increase in plasma cytokines or other factors in response to respiratory infection with C. pneumoniae or infection of macrophages within the blood vessel could contribute to both calcification and fibrosis of advanced atherosclerotic lesions. Pseudomonas aeruginosa is equipped with a large arsenal of cell-associated and secreted virulence factors and can use them together to enhance its own virulence potential.
KW - Atherosclerosis
KW - Calcification
KW - Cytokines
KW - Infection
UR - http://www.scopus.com/inward/record.url?scp=84908190401&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908190401&partnerID=8YFLogxK
U2 - 10.1111/2049-632X.12185
DO - 10.1111/2049-632X.12185
M3 - Article
C2 - 24833344
AN - SCOPUS:84908190401
SN - 2049-632X
VL - 72
SP - 61
EP - 69
JO - FEMS Immunology and Medical Microbiology
JF - FEMS Immunology and Medical Microbiology
IS - 1
ER -